Kazia Therapeutics Ltd ADR (KZIA)vsMerck & Company Inc (MRK)
KZIA
Kazia Therapeutics Ltd ADR
$8.08
+0.75%
HEALTHCARE · Cap: $89.24M
MRK
Merck & Company Inc
$144.70
-2.49%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3548725% more annual revenue ($67.38B vs $1.90M). MRK leads profitability with a 3.6% profit margin vs 0.0%. KZIA appears more attractively valued with a PEG of 1.01. MRK earns a higher WallStSmart Score of 44/100 (D).
KZIA
Hold36
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KZIA.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$144.70
$60.04 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 312.4% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.5x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : KZIA
The strongest argument for KZIA centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 312.4% demonstrates continued momentum. PEG of 1.01 suggests the stock is reasonably priced for its growth.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : KZIA
The primary concerns for KZIA are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
KZIA profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
KZIA carries more volatility with a beta of 2.27 — expect wider price swings.
KZIA is growing revenue faster at 312.4% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kazia Therapeutics Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?